Review Trabectedin as a single agent and in combination with pegylated liposomal doxorubicin – activity against ovarian cancer cells

Marczak, Agnieszka

doi:10.5114/wo.2014.43153

Cited by 3 publications

(4 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ovarian cancer is termed 'the silent killer' due to its lack of obvious symptoms. Annually, >225,000 ovarian cancer cases are diagnosed and it causes 125,000 mortalities ( 1 ). Ovarian cancer is the most lethal gynecological malignancy in the United States ( 2 ).…”

Section: Introductionmentioning

confidence: 99%

“…Of the newly diagnosed cases, 70% are diagnosed at a late stage, for which the 5-year survival rate is 9–35% ( 3 ). For patients with advanced ovarian cancer, metastasis is one of the major causes of treatment failure and mortality ( 1 – 3 ). Thus, researching invasive and metastatic mechanisms is important for improving ovarian cancer-associated survival and cure rates.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Decreasing the ratio of matriptase/HAI-1 by downregulation of matriptase as a potential adjuvant therapy in ovarian cancer

Sun

Jiang

Chen

et al. 2016

Molecular Medicine Reports

View full text Add to dashboard Cite

Tumor invasion and metastasis are complex biological processes. Matriptase and its endogenous inhibitor, hepatocyte growth factor activator inhibitor-1 (HAI-1) are involved in invasion and metastasis. To evaluate the ratio of matriptase/HAI-1 and their potential therapeutic value in ovarian cancer, HO-8910 human ovarian cancer cells and the homologous high-metastatic HO-8910PM cells were used as in vitro cellular models ovarian cancer. The invasive and metastatic abilities, and the expression of matriptase and HAI-1 in these cells were detected using scratch assays, Transwell chamber assays, reverse transcription-quantitative polymerase chain reaction, western blotting and fluorescent immunocytochemistry. Following infection with lentivirus-mediated matriptase-targeting small interfering RNA (siRNA), cell cycle progression and apoptosis were also analyzed. The migration distance and number of invading HO-8910PM cells were significantly increased compared with HO-8910 cells. HO-8910PM cells exhibited a significantly higher ratio of matriptase/HAI-1 mRNA levels compared with HO-8910 cells (0.51 vs. 0.24, ~2.2 fold increase). Compared with HO-8910 cells, the matriptase mRNA level was increased by ~3.6 fold in HO-8910PM cells, whereas the HAI-1 mRNA level was increased by ~1.7 fold. Similar increases in protein expression levels were also observed in HO-8910PM cells compared with HO-8910 cells. Migration and invasiveness were positively correlated with matriptase expression level (r=0.994, P<0.01) and the ratio of matriptase/HAI-1 (r=0.929, P<0.01). Downregulation of matriptase using siRNA resulted in inhibition of the invasive and metastatic abilities of HO-8910PM cells, cell cycle arrest in the G0/G1 phase and increased apoptosis. The present study demonstrated that ovarian cancer cell metastasis and invasion were more dependent on upregulation of matriptase levels than downregulation of HAI-1. Matriptase may be a potential adjuvant therapeutic target for inhibiting ovarian cancer invasion and metastasis.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Decreasing the ratio of matriptase/HAI-1 by downregulation of matriptase as a potential adjuvant therapy in ovarian cancer

Sun

Jiang

Chen

et al. 2016

Molecular Medicine Reports

View full text Add to dashboard Cite

show abstract

“…The issue of conserving the ovaries at hysterectomy in premenopausal women with benign gynecologic disease has been the subject of considerable controversy [ 1 – 5 ]. Some clinicians prefer prophylactic oophorectomy in premenopausal women during hysterectomy to prevent future development of malignant changes in conserved ovaries [ 6 – 16 ].…”

Section: Introductionmentioning

confidence: 99%

Ovarian function and ovarian blood supply following premenopausal abdominal hysterectomy

Abdelazim¹,

Abdelrazak²,

Elbiaa³

et al. 2015

View full text Add to dashboard Cite

IntroductionThe issue of conserving the ovaries at hysterectomy in premenopausal women with benign gynecologic disease has been the subject of considerable controversy. Some clinicians prefer prophylactic oophorectomy in premenopausal women during hysterectomy to prevent future development of malignant changes in conserved ovaries. Other clinicians prefer to conserve apparently normal ovaries, because bilateral oophorectomy in premenopausal women results in an abrupt imbalance, sudden onset of menopausal symptoms, decreased libido, increased cardiovascular risk and osteoporosis.Material and methodsTwo hundred and twenty multipara women (who had completed their families), with benign uterine pathology were included in this prospective study for abdominal hysterectomy with bilateral ovarian preservation. Pre-operative vaginal ultrasound, Doppler studies, diagnostic hysteroscopy and endometrial biopsy were done followed by laboratory studies including Anti-mullerian hormone (AMH), follicle stimulating hormone (FSH) and estradiol for all studied women. Doppler studies, AMH, FSH and estradiol were repeated 6 and 12 months post-operative for assessment of the ovarian function and ovarian blood supply after hysterectomy.ResultsPre-operative AMH, FSH and estradiol of the studied women were statistically insignificant compared to AMH, FSH and estradiol 6 and 12 months post-operative. Twelve months post-operative right and left ovarian volumes (6.92 ± 0.18 and 6.85 ± 0.19 cm3, respectively) were significantly larger than pre-operative right and left ovarian volumes (6.19 ± 0.22 and 5.86 ± 0.23 cm3, respectively), and, 12 months post-operative right and left ovarian pulsatility indices (2.92 ± 0.15 and 2.96 ± 0.16 cm/s, respectively) were significantly lower than pre-operative right and left ovarian pulsatility indices (3.45 ± 0.19 and 3.36 ± 0.2 cm/s, respectively). Eight (3.6%) cases of the studied women developed an ovarian cyst 6 months after hysterectomy, 3 were spontaneously resolved and the remaining 5 (2.27%) cases underwent exploratory laparotomy.ConclusionsThere is no evidence of ovarian dysfunction affecting conserved ovaries one year after hysterectomy in premenopausal women as evident by AMH, FSH and estradiol. Furthermore, an increased ovarian volume and reduced ovarian pulsatility indices indicate a possible increase in ovarian blood supply, and preserved non-compromised ovarian function.

show abstract

“…The lack of efficient and early detection is the reason for its high mortality rate (1). Ovarian cancer is the fourth leading cause of cancer death in women and has the highest mortality rate among all gynecological cancers.…”

Section: Introductionmentioning

confidence: 99%

E ects of di erent drug treatments on the proliferation of human ovarian carcinoma cell line MDAH-2774

2018

Turk J Med Sci

View full text Add to dashboard Cite

Review Trabectedin as a single agent and in combination with pegylated liposomal doxorubicin – activity against ovarian cancer cells

Cited by 3 publications

References 23 publications

Decreasing the ratio of matriptase/HAI-1 by downregulation of matriptase as a potential adjuvant therapy in ovarian cancer

Decreasing the ratio of matriptase/HAI-1 by downregulation of matriptase as a potential adjuvant therapy in ovarian cancer

Ovarian function and ovarian blood supply following premenopausal abdominal hysterectomy

E ects of di erent drug treatments on the proliferation of human ovarian carcinoma cell line MDAH-2774

Contact Info

Product

Resources

About